文献速递结核与非结核分枝杆菌

来自3期试验的药代动力学-药效学证据支持结核病利福平固定剂量给药

Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2024-01-01

本研究基于3期试验Study 31/ACTG 5349,分析利福平暴露与疗效及安全性结局的关系。群体药代动力学模拟显示固定剂量与按体重分层给药暴露覆盖相似;暴露低于中位数者与高于中位数者的稳定培养转阴及结核相关不良结局风险相似,利福平暴露升高与3级或以上不良事件或严重不良事件增加无关。

要点

  • 固定剂量利福平600 mg每日一次提供的暴露覆盖与按体重分层剂量相似。
  • 利福平暴露低于中位数者与高于中位数者的稳定培养转阴及结核相关不良结局风险相似。
  • 利福平暴露升高与3级或以上不良事件或严重不良事件增加无关。

核心结论

  • 固定剂量利福平600 mg每日一次可能是现行按体重分层给药策略用于标准6个月方案的合理替代。
  • 未来研究应评估利福平的最佳给药策略,剂量高于当前推荐。

研究设计与样本

  • 研究基于3期临床试验Study 31/ACTG 5349(NCT02410772),对照组方案所有参与者每日接受利福平600 mg固定剂量。
  • 采用群体非线性混合效应模型分析利福平浓度时间曲线,并比较固定剂量与按体重分层给药的模拟暴露。
  • 暴露-疗效分析纳入n=680,暴露-安全性分析纳入n=722。

主要发现

  • 模型推导的利福平暴露范围为4.57 mg·h/L至140.0 mg·h/L,中位数为41.8 mg·h/L。
  • 药代动力学模拟显示固定剂量利福平提供的暴露覆盖与按体重分层剂量相似。
  • 暴露-疗效分析(n=680)显示,利福平暴露低于中位数的参与者与高于中位数者相比,稳定培养转阴和结核相关不良结局的风险相似。
  • 暴露-安全性分析(n=722)显示,利福平暴露增加与3级或以上不良事件或严重不良事件增加无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal dosing strategy for rifampicin in treating drug-susceptible tuberculosis (TB) is still highly debated. In the phase 3 clinical trial Study 31/ACTG 5349 (NCT02410772), all participants in the control regimen arm received 600 mg rifampicin daily as a flat dose. Here, we evaluated relationships between rifampicin exposure and efficacy and safety outcomes. METHODS: We analyzed rifampicin concentration time profiles using population nonlinear mixed-effects models. We compared simulated rifampicin exposure from flat- and weight-banded dosing. We evaluated the effect of rifampicin exposure on stable culture conversion at 6 months; TB-related unfavorable outcomes at 9, 12, and 18 months using Cox proportional hazard models; and all trial-defined safety outcomes using logistic regression. RESULTS: Our model-derived rifampicin exposure ranged from 4.57 mg · h/L to 140.0 mg · h/L with a median of 41.8 mg · h/L. Pharmacokinetic simulations demonstrated that flat-dosed rifampicin provided exposure coverage similar to the weight-banded dose. Exposure-efficacy analysis (n = 680) showed that participants with rifampicin exposure below the median experienced similar hazards of stable culture conversion and TB-related unfavorable outcomes compared with those with exposure above the median. Exposure-safety analysis (n = 722) showed that increased rifampicin exposure was not associated with increased grade 3 or higher adverse events or serious adverse events. CONCLUSIONS: Flat-dosing of rifampicin at 600 mg daily may be a reasonable alternative to the incumbent weight-banded dosing strategy for the standard-of-care 6-month regimen. Future research should assess the optimal dosing strategy for rifampicin, at doses higher than the current recommendation.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ngo HX, Xu AY, Velásquez GE, et al. Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clin Infect Dis. 2024. PMID: 38462673. doi:10.1093/cid/ciae119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。